Dr. Shari B. Rudoler, MD

Dr. Rudoler practices at Jefferson Torresdale Hospital in Philadelphia, Pennsylvania, part of Thomas Jefferson University.

Dr. Rudoler's NPI, 1972525400, was assigned on July 24, 2006. Dr. Rudoler graduated from Perelman School of Medicine - Philadelphia in 1991. Dr. Rudoler holds Pennsylvania license MD-051229-L.

Dr. Rudoler's primary practice is Jefferson Torresdale Hospital, at 10800 Knights Road, Philadelphia, PA 19114 in Philadelphia County. The practice phone is (215) 612-4000.

Dr. Rudoler's primary practice is Jefferson Torresdale Hospital in Philadelphia, Pennsylvania, part of Thomas Jefferson University. Dr. Rudoler is also affiliated with Thomas Jefferson University Hospital. The medical group on file is Jefferson University Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rudoler practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Rudoler's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Rudoler is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Rudoler's licenses on file in 3 states: Pennsylvania, Delaware and Maryland.

Dmand AI lists bone cancer radiation, brain cancer radiation, breast cancer radiation, cervical cancer radiation, head & neck cancer radiation and lung cancer radiation among the conditions Dr. Rudoler treats.

CMS data shows 1,358 Medicare services from Dr. Rudoler across 20 procedure codes in 2024, for 129 Medicare patients. Medicare paid $89,287 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 129 Medicare patients who saw Dr. Rudoler in 2024. The largest group is 65 to 74, with 72 patients. 75% of them have cancer, and 75% have high blood pressure. 26% are also on Medicaid. Their average risk score is 2.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rudoler's median patient age at 70, with 69% women.

In 2024, Dr. Rudoler wrote 131 Medicare Part D claims for 62 patients. 90% of them were for generic drugs. CMS names the drug for 41 of them, across 2 drugs with 11 or more claims each, at $794 in total drug cost. In 2023, CMS named 37 claims across 2 drugs.

Dr. Rudoler accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 8 papers to Dr. Rudoler, published from 2017 to 2025. The most frequent topics are Radiation Oncology. Dr. Rudoler has published most often in Int J Radiat Oncol Biol Phys. Dr. Rudoler's most frequent co-authors are Eric L. Gressen, MD, Minal Milind Dhamankar, MD and Jessie W. Dinome, MD.

Dmand AI links Dr. Rudoler to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Brain Neoplasms, Breast Neoplasms, Male and Neoplasm Metastasis.

CMS Open Payments shows 304 general payments to Dr. Rudoler from 35 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Novartis Pharmaceuticals Corporation paid the most, $530.

Dr. Rudoler graduated from Perelman School of Medicine - Philadelphia in 1991.

Dr. Rudoler is in network with 9 carriers, including Elevance, Highmark and Cigna. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.